NCT00885820View on ClinicalTrials.gov

Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection

PHASE4CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

July 31, 2004

Study Completion Date

January 31, 2006

Conditions
Kidney Transplantation
Interventions
DRUG

Tacrolimus

Oral

DRUG

MMF

Oral

DRUG

Corticosteroids (Prednisone)

Oral

Trial Locations (12)

94304-1510

Palo Alto

T2N 2T9

Calgary

T6G 2B7

Edmonton

V5Z 1M9

Vancouver

V6Z 1Y6

Vancouver

R3A 1R9

Winnipeg

L8N 4A6

Hamilton

K1H 7W9

Ottawa

H1T 2M4

Montreal

H2L 4M1

Montreal

G1R 2J6

Québec

S7M 0Z9

Saskatoon

Sponsors
All Listed Sponsors
collaborator

Astellas Pharma Canada, Inc.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY

NCT00885820 - Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection | Biotech Hunter | Biotech Hunter